Next Phase Newsletter

A venture fund founded and headquartered in the US invests in early-stage companies that focus on reproductive and maternal health typically in Seed and Series A. The fund is impact focused to improve accessibility, affordability, innovation, and systemic change within women’s health. Typical check size is about $1M for the initial round and up to $3M across company lifespan. The firm will both lead and co-invest in global companies.

The firm invests across all healthcare segments: therapeutics, digital health, devices, diagnostics, etc. from pre-clinical to clinical stages as it relates to reproductive and maternal health.

The firm does not have specific management team requirements. The firm may take a board seat depending on the case. The firm would at least like to take an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A a life science specialist venture fund manager with offices in Europe and Asia has multiple billion dollars of assets under management. The firm invests in preclinical to clinical-stage life science companies, primarily in the field of therapeutic drug development with products addressing high unmet medical need and complementing Pharma’s pipelines. The firm deploys its capital with a geographic focus on Europe (~2/3 of investments) and North America (~1/3 of investments). Currently, the firm invests out of two new funds: one of them is focusing on preclinical to early clinical-stage assets; and the other one is focusing on private growth capital, cross-over/IPO rounds and PIPE investments in clinical-stage companies. The typical investment per round is €35-50M for both funds.

The firm invests in preclinical to clinical-stage life science companies, primarily in the field of therapeutic drug development with products addressing high unmet medical need and complementing Pharma’s pipelines.

The firm seeks a company with a strong and experienced management team and/or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A strategic venture firm backed by a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere, focuses on early and growth stage digital health and tech-enabled healthcare services companies. Initial allocations are typically from $5-10 million with the possibility of follow-on investments up to $25 million.

The firm focuses on five areas of innovation in healthcare – pharma clinical and commercial services, data and analytics, oncology, pharmacy services, and new care models.

The firm is equally focused on financial returns and ways the firm can potentially contribute value beyond the capital investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in Western Europe focuses on deeptech, specifically covering their thesis of transformative and frontier technology – technical solutions that can vastly change and command a huge market. The firm invests in Pre-Seed and Seed stage companies. Typical check size is a fixed amount of $500k USD, and the firm can act both as a lead or co-investor. The firm is geographically agnostic, but has made most of its investments in Europe and the USA.

In terms of life science, the firm considers digital health and sometimes device or diagnostic companies that have an AI component or some sort of consumer facing platform. The firm can go as early as the pre-revenue concept stage, right through to those with a sustained record of aggressive growth.

The firm does not have management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A women-led venture capital firm headquartered in the US is led by a team that brings together expertise in both healthcare and venture capital and can help build industry-transforming companies with exponential impact and returns. The firm is currently investing from their first fund in Seed to Series B technology start-ups that address healthcare problems such as uncured and unmanaged disease, lack of access to care, poor quality and medical errors, health disparities, and unsustainable costs. The firm is open to global companies as 20% of the fund is invested internationally. The firm both co-invests and leads rounds with initial check sizes ranging from $250k-2.5M.

The firm invests in diagnosis, delivery of care (digital health), and technologies to enable drug discovery and development with the underlying thesis of data and AI. The firm does not invest in traditional pharma or therapeutics companies. The firm is indication-agnostic. Typically, the firm invests in companies generating revenue but is open to investing pre-revenue for particularly compelling technologies.

The firm often requires taking an observer or board seat. The firm does not have specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A healthcare-focused investment firm had its beginnings as a CRO, helping companies execute clinical trials. This is still an important component of the firm’s unique business model, but in addition to this, the firm now seeks to actively invest in promising projects like a traditional venture capital fund. In addition to investing in companies, the firm seeks to leverage its capabilities to help companies with clinical trials in Central Asia. Executing clinical trials in Central Asia is much cheaper, allowing companies to validate their technologies on a faster, efficient basis. The firm is capable of investing $15-20M over the company’s lifecycle, and seeks companies globally.
Within life sciences, the firm seeks opportunities in therapeutics and medtech. Ideally, the firm seeks to engage in companies who are in early clinical stage – beyond Phase I – but is open to engaging with earlier projects. The firm is opportunistic in term of subsector and indication.

The firm seeks companies backed by innovative science and experienced management teams. As mentioned earlier, the firm is equipped to help companies execute clinical trials on a faster, more efficient basis, and has deep relationships with regional governments and leading institutions to make this possible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the US with additional offices in China has built three arms to support their portfolio companies, which is broken down to the following: (1) Investment: The firm invests in early-stage life science ventures, from Seed to Series B, with Series A and Series B being the firm’s sweet spot. Typical size of investment ranges from $1-2M in seed stage companies, and $3-5M in venture round companies. (2) Advisory Service to C-Suite: The firm supports entrepreneurs to expand to the Chinese market, and the firm has multiple offices in China and needed expertise to support the entrepreneur’s vision. (3) Analytics arm: The firm plays a fundamental role in deal sourcing and market trend analysis based on their proprietary data platform. Currently, the firm is most interested in companies based in USA, Israel, and Western Europe, particularly companies in the Nordic region.
The firm will consider therapeutics, medical devices, diagnostics, and life science tools. The firm is most interested in medical devices, and their interests include medtech and biotech combination products, novel methods of drug delivery, in vitro diagnostics (novel instruments and reagents), etc. The firm is interested in both 510K and PMA devices. Within therapeutics, the firm is more interested in clinical assets and typically do not look at pre-clinical companies unless the opportunity is compelling. Current main indication areas of interest for the firm are cardiovascular disease, oncology, and women’s health.

The firm seeks to work with management teams who are passionate about their technology and dedicated to creating values for the larger community. Though the firm is able to support companies who are interested in entering the China market, having a China angle is not necessary for investment. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.